Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of
[18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal
cancers, including hepatocellular carcinoma, cholangiocarcinoma, gastric, pancreatic and
colorectal cancer. The [18F]FAPI-74 PET scan will be acquired in patients with proven GI
cancers after initial staging using institutional standard methods. The PET scan results will
be compared to FAP immunohistochemistry (as the primary objective) and histopathology (as the
secondary objective) of the biopsied or resected tissues.